Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.

Phase 4 Completed 36 enrolled Stanford University Johns Hopkins University · collab National Institute on Drug Abuse (NIDA) · collab SRI International · collab University of Bristol · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.

Timeline

Start: 2009-07
Primary completion: 2011-03
Completion: 2011-03

Publications

Results McClure JB, Swan GE, St John J, Fauver R, Javitz HS, Bergen AW, Nishita D, Niaura R, Munafo MR, David SP. Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study. Nicotine Tob Res. 2013 Feb;15(2):518-26. doi: 10.1093/ntr/nts173. Epub 2012 Sep 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupropion	Small molecule	—	—
Subject	Nicotine	Unknown	—	Other

Indications

No indication recorded.